UNSPSC 51401505: Alprazolam

This classification denotes a benzodiazepine with the molecular formula C17H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YU55MQ3IZY, chemically known as 8-chloro-1-methyl-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine but generally known as alprazolam, which bears US NIH Compound Identifier 2118. Alprazolam most often comes in base and dihydrate forms. European Medicines Agency schedules Alprazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05370MIG.

UNSPSC 51401505 Alprazolam is a Commodity code that encompasses procurement of specific pharmaceutical products by state and local health agencies, though recent solicitations show limited direct purchasing of alprazolam itself and instead reflect broader pharmaceutical procurement patterns across multiple drug categories and delivery channels. State and local governments acquire pharmaceuticals under this code through direct purchases, cooperative purchasing agreements, and pharmacy benefit management arrangements that serve public health agencies, employee health plans, and community health programs. The issuing bodies include state health and human services departments, county health authorities, and multistate cooperative purchasing organizations that bundle pharmaceutical procurement across participating jurisdictions to achieve volume discounts and standardized supply chain management.

Activity appears concentrated in Texas and Minnesota, with secondary activity in Florida. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Minnesota's multistate cooperative, MMCAP, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities across Minnesota and Oregon, with contract term effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Seminole County, Florida solicited through IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems with annual volumes of 1,900 and 800 units respectively, delivered quarterly to county health facilities. Vendors pursuing this code should expect cGMP certification, Drug Supply Chain Security Act compliance, E-Verify requirements, and substantial liability insurance ($2–5 million) when responding to multistate cooperative or larger county procurements.